Omalizumab therapy in adolescents with severe allergic asthma - Results of a post-marketing surveillance;Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma - eine Anwendungsbeobachtung

Pneumologie

Volumn 67, Issue 4, 2013, Pages 233-237

  Klyucheva, M ^a   Von Berg, A ^a   Gappa, M ^a   Suerbaum, C ^a   Berdel, D ^a  

^a Marien Hospitals Wesel   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB;

ADD ON THERAPY; ADULT; ALLERGIC ASTHMA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE EXACERBATION; DRUG WITHDRAWAL; EMERGENCY CARE; HUMAN; LUNG FUNCTION TEST; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SERUM SICKNESS; TREATMENT DURATION;

ADOLESCENT; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; CHRONIC DISEASE; FEMALE; HUMANS; HYPERSENSITIVITY; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876109406     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0032-1326356     Document Type: Article

References (17)

1. World Health Organisation Asthma Health Topic. Available at: http://www.who.int/topics/asthma/en/ Last accessed: December 2011.
2. Price D. The use of omalizumab in asthma. Primary Care Respiratory Journal: 2008; 17 62 72 (Pubitemid 351847083)
3. Asher M. I., Montefort S., Björksten B. et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet: 2006; 368 733 743 (Pubitemid 44279052)
4. Eder W., Engel M. J., von Mutius E. The asthma epidemic. N Engl J Med: 2006; 355 2226 2235 (Pubitemid 44791164)
5. Chipps B. E., Szefler S. J., Simons F. ER et al. Demographic and clinical characterictics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol: 2007; 119 1156 1163 (Pubitemid 46654173)
6. Gould H. J., Sutton B. J. IgE in allergy and asthma today. Nature Revs Immunol: 2008; 8 205 217 (Pubitemid 351323292)
7. Holgate S., Casale T., Wenzel S. et al. The anti-inflamatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol: 2005; 60 305 316
8. Steiß J. O., Geidel C., Strohner P. et al. Therapiemonitoring von Omalizumab im Kindes- und Jugendalter - Auswirkungen auf die gesamt-IgE-Konzentration. Allergologie: 2010; 3 421 428
9. Busse W. W., Morgan W. J., Gergen P. J. et al. Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. N Eng J Med: 2011; 364 1005 1015
10. Nationale Versorgungsleitlinien Asthma. 2. Aufl.: 2010; http://www.Asthma.versorgungsleitlinien.de
11. Global Initiative on Asthma GINA Report, Global Strategy for Asthma Management and Prevention, Update. 2009
12. Novartis Pharma AG Fachinformation zu Xolair. Stand Juni 2011
13. Kulus M., Hebert J., Garsia E. et al. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin: 2010; 26 1285 1293
14. Humbert M., Beasley R., Ayres J. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy: 2005; 60 309 316 (Pubitemid 40293346)
15. Schumann C., Kropf C., Wibmer T. et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J: 2011; [Epub ahead of print]
16. Milgrom H., Fowler-Taylor A., Vidaurre C. F. et al. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin: 2011; 27 163 169
17. Tzortzaki E. G., Georgiou A., Kampas D. et al. Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean "real-lifeo" experience. Pulm Pharmacol Ther: 2012; 25 77 82